Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Net Income towards Common Stockholders (2016 - 2025)

Guided Therapeutics' Net Income towards Common Stockholders history spans 16 years, with the latest figure at -$1.2 million for Q4 2025.

  • On a quarterly basis, Net Income towards Common Stockholders fell 70.86% to -$1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.3 million, a 27.36% decrease, with the full-year FY2025 number at -$3.3 million, down 27.36% from a year prior.
  • Net Income towards Common Stockholders hit -$1.2 million in Q4 2025 for Guided Therapeutics, down from -$785000.0 in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for GTHP hit a ceiling of -$51000.0 in Q3 2021 and a floor of -$1.9 million in Q4 2022.
  • Historically, Net Income towards Common Stockholders has averaged -$845700.0 across 5 years, with a median of -$771500.0 in 2024.
  • Biggest five-year swings in Net Income towards Common Stockholders: soared 82.87% in 2021 and later crashed 1966.67% in 2022.
  • Tracing GTHP's Net Income towards Common Stockholders over 5 years: stood at -$509000.0 in 2021, then crashed by 264.83% to -$1.9 million in 2022, then skyrocketed by 74.74% to -$469000.0 in 2023, then plummeted by 49.25% to -$700000.0 in 2024, then plummeted by 70.86% to -$1.2 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for GTHP at -$1.2 million in Q4 2025, -$785000.0 in Q3 2025, and -$856000.0 in Q2 2025.